<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2021.105033</article-id><article-id pub-id-type="publisher-id">PI-44990</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20210500000_69633458.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  他汀类药物对肝病治疗作用的研究进展
  Research Progress of Statins in the Treatment of Liver Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>曾庆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>玉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>树军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>史</surname><given-names>红军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>连平</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>南京市高淳人民医院呼吸科，江苏 南京</addr-line></aff><aff id="aff2"><addr-line>南京市高淳人民医院药学部，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>08</month><year>2021</year></pub-date><volume>10</volume><issue>05</issue><fpage>261</fpage><lpage>267</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨他汀类药物对肝病治疗作用的研究现状，为他汀类药物对肝脏疾病的益处提供依据。方法：通过查阅国内外文献，本文总结了他汀类药物对肝脏疾病益处的最新研究进展。结果：他汀类药物的使用对慢性病毒性肝炎、缺氧性肝炎、非酒精性脂肪肝病、肝硬化、肝脏缺血–再灌注损伤、胆汁淤积和肝癌等肝脏疾病具有有益作用，其安全性也较为可靠。结论：他汀类药物在肝病治疗中的潜力日益突出，其在肝病治疗中的作用值得进一步研究。 Objective: To explore the status of statins in the treatment of liver disease, and to provide evidence for the benefit of statins in liver disease. Methods: By reviewing the domestic and foreign literature, this paper summarizes the latest research progress of the benefits of statins in treating liver diseases. Results: The use of statins has beneficial effects on liver diseases such as chronic viral hepatitis, hypoxic hepatitis, nonalcoholic fatty liver disease, cirrhosis, liver ischemia-reperfusion injury, cholestasis and liver cancer. Its security is also reliable. Conclusion: The potential of statins in the treatment of liver disease is increasingly prominent, and its role in the treatment of liver diseases is worth further study. 
  
 
</p></abstract><kwd-group><kwd>他汀类药物，肝脏疾病，治疗，益处, Statins</kwd><kwd> Liver Disease</kwd><kwd> Treatment</kwd><kwd> Benefits</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨他汀类药物对肝病治疗作用的研究现状，为他汀类药物对肝脏疾病的益处提供依据。方法：通过查阅国内外文献，本文总结了他汀类药物对肝脏疾病益处的最新研究进展。结果：他汀类药物的使用对慢性病毒性肝炎、缺氧性肝炎、非酒精性脂肪肝病、肝硬化、肝脏缺血–再灌注损伤、胆汁淤积和肝癌等肝脏疾病具有有益作用，其安全性也较为可靠。结论：他汀类药物在肝病治疗中的潜力日益突出，其在肝病治疗中的作用值得进一步研究。</p></sec><sec id="s2"><title>关键词</title><p>他汀类药物，肝脏疾病，治疗，益处</p></sec><sec id="s3"><title>Research Progress of Statins in the Treatment of Liver Diseases<sup> </sup></title><p>Zengqing Ma<sup>1*</sup>, Yu Lin<sup>2</sup>, Shujun Zhou<sup>1</sup>, Hongjun Shi<sup>1</sup>, Lianping Wu<sup>1#</sup></p><p><sup>1</sup>Department of Pharmacy, Nanjing Gaochun People’s Hospital, Nanjing Jiangsu</p><p><sup>2</sup>Department of Respiratory, Nanjing Gaochun People’s Hospital, Nanjing Jiangsu</p><p><img src="//html.hanspub.org/file/3-1710291x5_hanspub.png?20210906092037603" /></p><p>Received: Jul. 31<sup>st</sup>, 2021; accepted: Aug. 26<sup>th</sup>, 2021; published: Sep. 3<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-1710291x6_hanspub.png?20210906092037603" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the status of statins in the treatment of liver disease, and to provide evidence for the benefit of statins in liver disease. Methods: By reviewing the domestic and foreign literature, this paper summarizes the latest research progress of the benefits of statins in treating liver diseases. Results: The use of statins has beneficial effects on liver diseases such as chronic viral hepatitis, hypoxic hepatitis, nonalcoholic fatty liver disease, cirrhosis, liver ischemia-reperfusion injury, cholestasis and liver cancer. Its security is also reliable. Conclusion: The potential of statins in the treatment of liver disease is increasingly prominent, and its role in the treatment of liver diseases is worth further study.</p><p>Keywords:Statins, Liver Disease, Treatment, Benefits</p><disp-formula id="hanspub.44990-formula18"><graphic xlink:href="//html.hanspub.org/file/3-1710291x7_hanspub.png?20210906092037603"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1710291x8_hanspub.png?20210906092037603" /> <img src="//html.hanspub.org/file/3-1710291x9_hanspub.png?20210906092037603" /></p></sec><sec id="s5"><title>1. 引言</title><p>他汀类药物是3-羟基-3-甲基戊二酰基辅酶A (3-hydroxy-3-methylglutaryl coenzyme A, HMG-CoA)还原酶抑制剂，通过阻止HMG-CoA转化为甲羟戊酸盐，降低低密度脂蛋白(low-density lipoprotein, LDL)受体的表达，降低血浆LDL和总胆固醇水平 [<xref ref-type="bibr" rid="hanspub.44990-ref1">1</xref>]。除调脂作用外，其还具有抗增殖、促凋亡、抗血管生成、抗炎、抗感染、免疫调节和抗肿瘤等作用 [<xref ref-type="bibr" rid="hanspub.44990-ref2">2</xref>]。此外，最新的研究发现，他汀类药物在多种慢性肝病(chronic liver diseases, CLDs)及其并发症的治疗中发挥着有益作用，包括慢性病毒性肝炎、非酒精性脂肪肝病、肝硬化和肝癌等 [<xref ref-type="bibr" rid="hanspub.44990-ref3">3</xref>]。本文从治疗效果和作用机制等方面总结了近年来他汀类药物治疗肝脏疾病的最新进展，以期为肝病和其并发症的治疗提供新的思路。</p></sec><sec id="s6"><title>2. 他汀类药物临床应用现状</title><p>他汀类药物于1987年开始上市，主要用于高胆固醇血症和冠心病的一、二级预防。鉴于他汀类药物良好的疗效和庞大的适应症人群，其已成为全球第二大最常用的处方药。目前，洛伐他汀、辛伐他汀、阿托伐他汀、氟伐他汀、普伐他汀、瑞舒伐他汀和匹伐他汀在临床上较为常用 [<xref ref-type="bibr" rid="hanspub.44990-ref4">4</xref>]。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Intensity of statin therap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >强度等级</th><th align="center" valign="middle" >高效</th><th align="center" valign="middle" >中效</th><th align="center" valign="middle" >低效</th></tr></thead><tr><td align="center" valign="middle" >LDL-C降低幅度</td><td align="center" valign="middle" >≥50%</td><td align="center" valign="middle" >30%~49%</td><td align="center" valign="middle" >&lt;30%</td></tr><tr><td align="center" valign="middle" >药物及用量</td><td align="center" valign="middle" >阿托伐他汀：40~80 mg 瑞舒伐他汀：20~40 mg</td><td align="center" valign="middle" >阿托伐他汀：10~20 mg 瑞舒伐他汀：5~10 mg 辛伐他汀：20~40 mg 普伐他汀：40~80 mg 洛伐他汀：40~80 mg 氟伐他汀缓释片：80 mg 氟伐他汀：40 mg bid 匹伐他汀：1~4 mg</td><td align="center" valign="middle" >辛伐他汀：10 mg 普伐他汀：10~20 mg 洛伐他汀：20 mg 氟伐他汀：20~40 mg</td></tr></tbody></table></table-wrap><p>表1. 他汀类药物的治疗强度</p><p>2018年美国心脏病学会降脂治疗指南根据不同方案中他汀类药物的治疗强度(即LDL-C的下降水平)，将其分为高、中、低效3类。经治疗后，高效治疗方案物通常可降低LDL-C水平50%以上，中效治疗方案可降低30%至49%，低效治疗方案则降低30%以下(见表1) [<xref ref-type="bibr" rid="hanspub.44990-ref5">5</xref>]。此外，Ryo等的研究显示，他汀类药物的降脂效果存在明显的种族差异，与西方人相比，他汀类药物在亚洲人身上的降脂作用效果更为明显，这可能是由于不同人种的基因型差异所导致的。</p></sec><sec id="s7"><title>3. 他汀类药物对多种肝脏疾病有治疗作用</title><sec id="s7_1"><title>3.1. 慢性病毒性肝炎</title><p>他汀类药物对艾滋病毒、脊髓灰质炎病毒、巨细胞病毒、登革热病毒和呼吸道合胞病毒等多种病毒都有抗病毒作用，最新的研究表明，其对乙型肝炎病毒(hepatitis B virus，HBV)和丙型肝炎病毒(hepatitis C virus，HCV)也均具有杀灭作用 [<xref ref-type="bibr" rid="hanspub.44990-ref5">5</xref>]。目前，常规的干扰素(interferon，IFN)和利巴韦林(riboviron，RVB)联合疗法仅对半数患者有效，并伴有严重的副作用。因此，开发更有效、更安全、耐受性良好的抗肝炎病毒药物是当务之急。</p><p>体外实验显示，洛伐他汀、辛伐他汀、阿托伐他汀、氟伐他汀和匹他汀均能够有效地抑制HBV和HCV的复制，其中洛伐他汀的作用最强，而普伐他汀并未表现出抗病毒作用 [<xref ref-type="bibr" rid="hanspub.44990-ref6">6</xref>]。此外，临床研究表明，在IFN/RVB的治疗中添加他汀类药物会增加持续性病毒应答率(sustained virological response, SVR) [<xref ref-type="bibr" rid="hanspub.44990-ref7">7</xref>]。该实验随机将101名慢性病毒性肝炎分配到IFN/RBV治疗组或IFN/RBV + 氟伐他汀(20 mg/d)治疗组，疗程为48~72周。两组的SVR分别为41.7%和63% (P = 0.04)。在另一项纳入7248名受试者的研究中，有46%的患者接受了他汀类药物治疗，与未使用者相比，他汀类药物的使用者的SVR明显升高(33.3% vs 39.2%, P &lt; 0.01) [<xref ref-type="bibr" rid="hanspub.44990-ref8">8</xref>]。他汀类药物抗病毒的作用机制尚不清楚，可能是通过抑制胆固醇和香叶酰化蛋白的合成来阻断病毒复制，从而降低关键的病毒蛋白表达并抑制炎症信号通路而发挥作用 [<xref ref-type="bibr" rid="hanspub.44990-ref9">9</xref>]。</p></sec><sec id="s7_2"><title>3.2. 缺氧性肝炎</title><p>缺氧性肝炎(hypoxic hepatitis, HH)，又称休克肝或缺血性肝炎，发病率和死亡率很高，严重危及人们的生命。一项纳入851例ICU患者的前瞻性研究显示，入院前他汀类药物的使用可以显著降低入院48小时内HH的发生率(OR = 0.42, 95% CI: 0.19~0.95, P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.44990-ref10">10</xref>]。该研究还提示，入院前他汀类药物治疗可以使HH患者入院28天内的死亡率显著下降(OR = 0.65, 95% CI: 0.43~0.99, P &lt; 0.05)。</p></sec><sec id="s7_3"><title>3.3. 非酒精性脂肪肝病</title><p>非酒精性脂肪肝病(nonalcoholic fatty liver disease, NAFLD)指在未过量摄入酒精和其他导致脂肪变性的原因下，肝脏中脂肪过度累积使甘油三酯的含量超过5% [<xref ref-type="bibr" rid="hanspub.44990-ref11">11</xref>]。它是世界范围内最常见的慢性肝病，全球约有25%到33%的人患有NAFLD [<xref ref-type="bibr" rid="hanspub.44990-ref12">12</xref>]。</p><p>尽管影响到全世界数以亿计的患者，但目前还没有药物被证明对NAFLD及其引起的肝组织纤维化有效。目前，NAFLD的治疗仅限于改变生活方式，如饮食和锻炼，以及共病的管理，如治疗血脂异常和肥胖 [<xref ref-type="bibr" rid="hanspub.44990-ref13">13</xref>]。幸运的是，最新的研究发现，他汀类药物对NAFLD显示出良好的治疗作用。Dongiovanni等在一个1201名患者(其中有107名他汀类药物使用者)的多中心队列研究中评估了他汀类药物的使用与NAFLD的关系 [<xref ref-type="bibr" rid="hanspub.44990-ref14">14</xref>]。研究显示，在NAFLD患者中，他汀类药物的使用对肝脏有保护作用且呈剂量依赖性，使用他汀类药物后肝脂肪变性的风险下降了91% (95% CI: 0.01~0.32, P = 0.004)、肝炎的风险下降了75% (95% CI: 0.13 ~0.47, P &lt; 0.001)和肝纤维化风险下降了58% (95% CI: 0.20~0.80, P = 0.017)。因此，在NAFDL治疗手段缺乏的今天，他汀类药物显得至关重要。</p></sec><sec id="s7_4"><title>3.4. 肝硬化</title><p>肝硬化是一个世界性的公共卫生问题，以肝结构扭曲、再生结节、血管生成为特征，并往往伴有门脉压力升高 [<xref ref-type="bibr" rid="hanspub.44990-ref15">15</xref>]。研究显示，他汀类药物对肝硬化以及其造成的门脉高压均具有良好的治疗作用。他汀类药物能够通过抑制TGF-b/Smad和RhoA/ROCK通路、上调KLF2表达等途径以减轻纤维化来缓解肝硬化患者的病情，并使死亡率由每千人12.7%下降至8.8% [<xref ref-type="bibr" rid="hanspub.44990-ref16">16</xref>]。2016年，台湾的一项病例对照研究显示，使用他汀类药物者的肝硬化发生风险会降低60%以上(95% CI: 0.344~0.515, P &lt; 0.001)，且肝硬化患者在使用他汀类药物后，失代偿风险降低了约50% (95% CI: 0.344~0.637, P &lt; 0.001) [<xref ref-type="bibr" rid="hanspub.44990-ref17">17</xref>]。此外，他汀类药物还能够促进内皮细胞释放NO而降低肝硬化患者的门脉高压。Bishnu等的研究显示，经阿托伐他汀治疗一周后，与未使用者相比，肝硬化患者的肝脏血流动力学得到明显改善，肝静脉楔入压、肝静脉自由压和肝静脉压力梯度均出现不同程度度的降低 [<xref ref-type="bibr" rid="hanspub.44990-ref18">18</xref>]。</p></sec><sec id="s7_5"><title>3.5. 肝脏缺血–再灌注损伤</title><p>肝脏缺血–再灌注损伤(ischaemia-reperfusion injury, IRI)是肝脏手术、循环性休克和急性心衰的重要并发症，其损害肝功能，甚至会导致原发性移植物衰竭或加速肝移植排斥反应 [<xref ref-type="bibr" rid="hanspub.44990-ref19">19</xref>]。他汀类药物可以通过抑制NF-κB缓解炎症、通过激活eNOS保护微血管以及抑制TXB2和MP的释放来预防IRI对肝脏造成的损伤。相关动物研究显示，部分肝切除大鼠在术前服用阿托伐他汀后，会显著减轻术后出现AST、ALT、TNF-a和ET-1等升高的幅度(P &lt; 0.05)，改善肝脏病理，保护肝脏免受IRI损伤 [<xref ref-type="bibr" rid="hanspub.44990-ref20">20</xref>]。在Sarin等 [<xref ref-type="bibr" rid="hanspub.44990-ref21">21</xref>] 的研究中，肝切除术前服用阿托伐他汀治疗后，患者的AST、IL-1和THF-α水平显著低于安慰剂对照组。上述研究均证实了他汀类药物对肝脏IRI具有预防保护作用。</p></sec><sec id="s7_6"><title>3.6. 胆汁淤积</title><p>胆汁淤积以胆汁酸为主的毒性胆汁化合物在肝内过度积聚为特征，导致肝组织炎症和氧化损伤。目前，仅有熊去氧胆酸被FDA批准用于胆汁淤积的治疗。最新的研究显示，普伐他汀、辛伐他汀、瑞舒伐他汀能够预防和治疗胆汁淤积性肝病。他汀类药物可以通过调节血红素的分解代谢、增加肝脏铁储存、抑制HMGB1/TLR4和miR-21的表达、阻止TNF-α和IL-6等炎性因子的生成来减轻胆汁淤积性肝损伤 [<xref ref-type="bibr" rid="hanspub.44990-ref22">22</xref>]。在一项单盲随机对照试验中，11例胆汁淤积性肝硬化患者在接受辛伐他汀治疗12个月后，各项生化指标均优于与安慰剂组 [<xref ref-type="bibr" rid="hanspub.44990-ref23">23</xref>]。然而，目前绝大多数研究为动物实验，临床研究较为缺乏且纳入的病例数较少。因此，他汀类药物对胆汁淤积的治疗作用还需要更大规模的临床研究来充分支持。</p></sec><sec id="s7_7"><title>3.7. 肝癌</title><p>肝癌是世界第六大常见的癌症，其恶性程度高，中位生存时间不足1年，是全球健康的一项重大挑战 [<xref ref-type="bibr" rid="hanspub.44990-ref24">24</xref>]。尽管相关指南已经提出在高危人群中进行肝癌筛查以预防及尽早治疗，但是许多患者发现时就已经处于晚期，尤其是与NAFLD相关的肝癌 [<xref ref-type="bibr" rid="hanspub.44990-ref25">25</xref>]。目前，肝癌的治疗药物极为有限，雪上加霜的是，一些药物对晚期肝癌的疗效较低，副作用也较大，如索拉菲尼。最新研究显示，他汀类药物通过抑制增殖、阻滞细胞周期、抑制侵袭和促凋亡等多种途径而发挥抗肝癌作用 [<xref ref-type="bibr" rid="hanspub.44990-ref24">24</xref>]。此外，还有大量的临床研究显示他汀类药物能够显著降低人们患肝癌的风险和患者的死亡率(表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical study on the relationship between statins and liver cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >主要研究者</th><th align="center" valign="middle"  rowspan="2"  >研究时间</th><th align="center" valign="middle"  colspan="2"  >患者例数</th><th align="center" valign="middle"  rowspan="2"  >研究结果</th></tr></thead><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >对照组</td></tr><tr><td align="center" valign="middle" >Hsiang [<xref ref-type="bibr" rid="hanspub.44990-ref26">26</xref>]</td><td align="center" valign="middle" >2015年</td><td align="center" valign="middle" >n = 1262</td><td align="center" valign="middle" >n = 52,337</td><td align="center" valign="middle" >他汀类药物使用者患肝癌风险降低32% (HR: 0.68, 95% CI: 0.68~0.97)</td></tr><tr><td align="center" valign="middle" >Thrift [<xref ref-type="bibr" rid="hanspub.44990-ref25">25</xref>]</td><td align="center" valign="middle" >2019年</td><td align="center" valign="middle" >n = 2293</td><td align="center" valign="middle" >n = 13,129</td><td align="center" valign="middle" >他汀类药物使用者肝癌死亡风险降低15% (HR: 0.85, 95% CI: 0.77~0.93)</td></tr><tr><td align="center" valign="middle" >Tran [<xref ref-type="bibr" rid="hanspub.44990-ref27">27</xref>]</td><td align="center" valign="middle" >2020年</td><td align="center" valign="middle" >n = 434</td><td align="center" valign="middle" >n = 2103</td><td align="center" valign="middle" >他汀类药物使用者患肝癌风险降低39% (HR: 0.61, 95% CI: 0.43~0.87)</td></tr><tr><td align="center" valign="middle" >Kim [<xref ref-type="bibr" rid="hanspub.44990-ref28">28</xref>]</td><td align="center" valign="middle" >2018年</td><td align="center" valign="middle" >n = 1642</td><td align="center" valign="middle" >n = 8210</td><td align="center" valign="middle" >他汀类药物使用者患肝癌风险降低56% (HR: 0.44, 95% CI: 0.33~0.58)； 治疗效果呈剂量依赖性</td></tr><tr><td align="center" valign="middle" >Chiu [<xref ref-type="bibr" rid="hanspub.44990-ref29">29</xref>]</td><td align="center" valign="middle" >2011年</td><td align="center" valign="middle" >n = 1166</td><td align="center" valign="middle" >n = 1166</td><td align="center" valign="middle" >他汀类药物使用者患肝癌风险降低38% (ORs: 0.62, 95% CI: 0.42~0.91)</td></tr><tr><td align="center" valign="middle" >Shao [<xref ref-type="bibr" rid="hanspub.44990-ref30">30</xref>]</td><td align="center" valign="middle" >2015年</td><td align="center" valign="middle" >n = 1988</td><td align="center" valign="middle" >n = 18,212</td><td align="center" valign="middle" >使用他汀类药物后，感染HBV的I~IV期肝癌患者死亡风险均下降(P &lt; 0.05)</td></tr></tbody></table></table-wrap><p>表2. 他汀类药物与肝癌关系的临床研究</p></sec></sec><sec id="s8"><title>4. 肝病患者使用他汀类药物的安全性</title><p>他汀类药物导致的严重肝功能损伤发生率极低，其诱发严重肌肉损伤(包括横纹肌溶解)的风险为0.1%，严重肝毒性的风险为0.001% [<xref ref-type="bibr" rid="hanspub.44990-ref31">31</xref>]。他汀类药物导致肝脏的损伤最常见的是血清转氨酶水平升高，通常发生在治疗的前12周，一般不会引起组织病理学改变，其通常为为自限性，停药后即可缓解。为避免不必要的停药，国际严重不良反应协会提出药物性肝损伤的生化诊断标准为出现以下任一情况：1) ALT ≥ 5 &#215; ULN；2) ALP ≥ 2 &#215; ULN；3) ALT ≥ 3 &#215; ULN且总胆红素 ≥ 2 &#215; ULN [<xref ref-type="bibr" rid="hanspub.44990-ref32">32</xref>]。</p><p>然而，他汀类药物在肝病患者中的肝毒性却存在一些争议，但也有研究表明，低至中剂量他汀类药物的治疗是安全的，而且肝毒性非常低，甚至对疾病状态下的肝功能有一定的改善作用。总体而言，他汀类药物可以在绝大多数肝病患者中安全使用。在使用他汀类药物过程中，应及时检查患者的肝功能，若患者出现无症状的单纯转氨酶升高 &lt; 3 &#215; ULN，则无需停药；若血清直接胆红素与转氨酶同时升高，提示有进行性肝损伤的可能性，建议停止服用他汀类药物；若出现严重肝损伤，应立即停药。</p></sec><sec id="s9"><title>5. 小结</title><p>目前，肝脏疾病已成为全球健康的一个重大挑战，一些肝脏疾病在今天仍缺乏足够的有效治疗手段。最新的体内、外研究均证实他汀类药物在病毒性肝炎、缺氧性肝炎、NAFLD、肝硬化、门脉高压、肝脏缺血再灌注损伤、胆汁淤积和肝癌等肝病中发挥着有益作用，通过多种途径延缓疾病进展、抑制肝炎病毒复制、抗纤维化、降低门脉压力、降低患癌风险和死亡率等。加之他汀类药物获取、使用的便捷性和价格的经济性，其在肝病治疗中的潜力日益突出。然而目前的相关研究很少涉及亚洲人，因此他汀类药物在大规模中国人群中的相关研究显得尤为需要。</p></sec><sec id="s10"><title>文章引用</title><p>马曾庆,林 玉,周树军,史红军,吴连平. 他汀类药物对肝病治疗作用的研究进展Research Progress of Statins in the Treatment of Liver Diseases[J]. 药物资讯, 2021, 10(05): 261-267. https://doi.org/10.12677/PI.2021.105033</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44990-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Blaha, M.J. and Martin, S.S. (2013) How Do Statins Work? Changing Paradigms with Implications for Statin Allocation. Journal of the American College of Cardiology, 62, 2392-2394. &lt;br&gt;https://doi.org/10.1016/j.jacc.2013.08.1626</mixed-citation></ref><ref id="hanspub.44990-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E. and Lippman, S.M. (2005) Statins and Cancer Prevention. Nature Reviews Cancer, 5, 930-942. &lt;br&gt;https://doi.org/10.1038/nrc1751</mixed-citation></ref><ref id="hanspub.44990-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pose, E., Trebicka, J., Mookerjee, R.P., Angeli, P. and Ginès, P. (2019) Statins: Old Drugs as New Therapy for Liver Diseases? Journal of Hepatology, 70, 194-202.</mixed-citation></ref><ref id="hanspub.44990-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Adhyaru, B.B. and Jacobson, T.A. (2018) Safety and Efficacy of Statin Therapy. Nature Reviews Cardiology, 15, 757-769. &lt;br&gt;https://doi.org/10.1038/s41569-018-0098-5</mixed-citation></ref><ref id="hanspub.44990-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., Braun, L.T., de Ferranti, S., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1082-e1143. &lt;br&gt;https://doi.org/10.1161/CIR.0000000000000700</mixed-citation></ref><ref id="hanspub.44990-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Verpaalen, B., Neyts, J. and Delang, L. (2014) Are Statins a Viable Option for the Treatment of Infections with the Hepatitis C Virus? Antiviral Research, 105, 92-99. &lt;br&gt;https://doi.org/10.1016/j.antiviral.2014.02.020</mixed-citation></ref><ref id="hanspub.44990-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Delang, L., Paeshuyse, J., Vliegen, I., Leyssen, P., Obeid, S., Durantel, D., et al. (2009) Statins Potentiate the in Vitro Anti-Hepatitis C Virus Activity of Selective Hepatitis C Virus Inhibitors and Delay or Prevent Resistance Development. Hepatology, 50, 6-16. &lt;br&gt;https://doi.org/10.1002/hep.22916</mixed-citation></ref><ref id="hanspub.44990-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kondo, C., Atsukawa, M., Tsubota, A., Itokawa, N., Fukuda, T., Matsu-shita, Y., et al. (2012) An Open-Label Randomized Controlled Study of Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C with versus without Fluvastatin. Journal of Viral Hepatitis, 19, 615-622. &lt;br&gt;https://doi.org/10.1111/j.1365-2893.2011.01584.x</mixed-citation></ref><ref id="hanspub.44990-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Butt, A.A., Yan, P., Bonilla, H., Abou-Samra, A.-B., Shaikh, O.S., Simon, T.G., et al. (2015) Effect of Addition of Statins to Antiviral Therapy in Hepatitis C Virus-Infected Persons: Results from ERCHIVES. Hepatology, 62, 365-374.  
&lt;br&gt;https://doi.org/10.1002/hep.27835</mixed-citation></ref><ref id="hanspub.44990-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bader, T., Fazili, J., Madhoun, M., Aston, C., Hughes, D., Rizvi, S., et al. (2008) Fluvastatin Inhibits Hepatitis C Replication in Humans. American Journal of Gastroenterology, 103, 1383-1389.</mixed-citation></ref><ref id="hanspub.44990-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Drolz, A., Horvatits, T., Michl, B., Roedl, K., Schellongowski, P., Holzinger, U., et al. (2014) Statin Therapy Is Associated with Reduced Incidence of Hypoxic Hepatitis in Critically Ill Patients. Journal of Hepatology, 60, 1187-1193.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2014.01.019</mixed-citation></ref><ref id="hanspub.44990-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Athyros, V.G., Katsiki, N., Karagiannis, A. and Mikhailidis, D.P. (2013) Statins and Nonalcoholic Fatty Liver Disease: A Bright Future? Expert Opinion on Investigational Drugs, 22, 1089-1093.  
&lt;br&gt;https://doi.org/10.1517/13543784.2013.824423</mixed-citation></ref><ref id="hanspub.44990-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. &lt;br&gt;https://doi.org/10.1002/hep.28431</mixed-citation></ref><ref id="hanspub.44990-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Pockros, P.J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E.J., et al. (2019) CONTROL: A Randomized Phase 2 Study of Obeticholic Acid and Atorvastatin on Lipoproteins in Nonalcoholic Steatohepatitis Patients. Liver International, 39, 2082-2093. &lt;br&gt;https://doi.org/10.1111/liv.14209</mixed-citation></ref><ref id="hanspub.44990-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Dongiovanni, P., Petta, S., Mannisto, V., Margherita Mancina, R., Pipitone, R., Karja, V., et al. (2015) Statin Use and Non-Alcoholic Steatohepatitis in at Risk Individuals. Journal of Hepatology, 63, 705-12.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2015.05.006</mixed-citation></ref><ref id="hanspub.44990-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Tsochatzis, E.A., Bosch, J. and Burroughs, A.K. (2014) Liver Cirrhosis. Lancet, 383, 1749-1761.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(14)60121-5</mixed-citation></ref><ref id="hanspub.44990-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Bang, U.C., Benfield, T. and Bendtsen, F. (2017) Reduced Risk of Decompensation and Death Associated with Use of Statins in Patients with Alcoholic Cirrhosis. A Nationwide Case-Cohort Study. Alimentary Pharmacology &amp; Therapeutics, 46, 673-680. &lt;br&gt;https://doi.org/10.1111/apt.14243</mixed-citation></ref><ref id="hanspub.44990-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y.W., Lee, C.L., Yang, S.S., Fu, S.-C., Chen, Y.-Y., Wang, T.-C., et al. (2016) Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. American Journal of Gastroenterology, 111, 976-985. &lt;br&gt;https://doi.org/10.1038/ajg.2016.179</mixed-citation></ref><ref id="hanspub.44990-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bishnu, S., Ahammed, S.M., Sarkar, A., Hembram, J., Chatterjee, S., Das, K., et al. (2018) Effects of Atorvastatin on Portal Hemodynamics and Clinical Outcomes in Patients with Cirrhosis with Portal Hypertension: A Proof-of-Concept Study. European Journal of Gastroenterology &amp; Hepatology, 30, 54-59.  
&lt;br&gt;https://doi.org/10.1097/MEG.0000000000001006</mixed-citation></ref><ref id="hanspub.44990-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ajamieh, H., Farrell, G.C., McCuskey, R.S., Yu, J., Chu, E., Wong, H.-J., et al. (2015) Acute Atorvastatin Is Hepatoprotective against Ischaemia-Reperfusion Injury in Mice by Modulating eNOS and Microparticle Formation. Liver International, 35, 2174-2186. &lt;br&gt;https://doi.org/10.1111/liv.12827</mixed-citation></ref><ref id="hanspub.44990-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Cámara-Lemarroy, C.R., Guzmán-de la Garza, F.J., Alarcón-Galván, G., Cordero-Pérez, P., Muñoz-Espinosa, L., Torres-González, L., et al. (2014) Hepatic Ischemia/Reperfusion Injury Is Di-minished by Atorvastatin in Wistar Rats. Archives of Medical Research, 45, 210-216. &lt;br&gt;https://doi.org/10.1016/j.arcmed.2014.02.001</mixed-citation></ref><ref id="hanspub.44990-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sarin, S., Kaman, L., Dahiya, D., Behera, A., Medhi, B. and Chawla, Y. (2016) Effects of Preoperative Statin on Liver Reperfusion Injury in Major Hepatic Resection: A Pilot Study. Updates in Surgery, 68, 191-197.  
&lt;br&gt;https://doi.org/10.1007/s13304-016-0370-3</mixed-citation></ref><ref id="hanspub.44990-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nabih, E.S. and El-Kharashi, O.A. (2019) Targeting HMGB1/TLR4 Axis and miR-21 by Rosuva Statin: Role in Alleviating Cholestatic Liver Injury in a Rat Model of Bile Duct Ligation. Naunyn-Schmiedeberg’s Archives of Pharmacology, 392, 37-43. &lt;br&gt;https://doi.org/10.1007/s00210-018-1560-y</mixed-citation></ref><ref id="hanspub.44990-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cash, W.J., O’Neill, S., O’Donnell, M.E., McCance, D.R., Young, I.S., McEneny, J., et al. (2013) Randomized Controlled Trial Assessing the Effect of Simvastatin in Primary Bil-iary Cirrhosis. Liver International, 33, 1166-1174.  
&lt;br&gt;https://doi.org/10.1111/liv.12191</mixed-citation></ref><ref id="hanspub.44990-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Kim, G. and Kang, E.S. (2019) Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms. Seminars in Liver Disease, 39, 141-152. &lt;br&gt;https://doi.org/10.1055/s-0039-1679956</mixed-citation></ref><ref id="hanspub.44990-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Thrift, A.P., Natarajan, Y., Liu, Y. and El-Serag, H.B. (2019) Statin Use after Diagnosis of Hepatocellular Carcinoma Is Associated with Decreased Mortality. Clinical Gastroenterology and Hepatology, 17, 2117-2125.e3.  
&lt;br&gt;https://doi.org/10.1016/j.cgh.2018.12.046</mixed-citation></ref><ref id="hanspub.44990-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Hsiang, J.C., Wong, G.L., Tse, Y.K., Wong, V.W.-S., Yip, T.C.-F. and Chan, H.L.-Y. (2015) Statin and the Risk of Hepatocellular Carcinoma and Death in a Hospital-Based Hepatitis B-Infected Population: A Propensity Score Landmark Analysis. Journal of Hepatology, 63, 1190-1197. &lt;br&gt;https://doi.org/10.1016/j.jhep.2015.07.009</mixed-citation></ref><ref id="hanspub.44990-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Tran, K.T., McMenamin, Ú.C., Coleman, H.G., Cardwell, C.R., Murchie, P., Iversen, L., et al. (2020) Statin Use and Risk of Liver Cancer: Evidence from Two Population-Based Stud-ies. International Journal of Cancer, 146, 1250-1260.  
&lt;br&gt;https://doi.org/10.1002/ijc.32426</mixed-citation></ref><ref id="hanspub.44990-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Kim, G., Jang, S.Y., Nam, C.M. and Kang, E.S. (2018) Statin Use and the Risk of Hepatocellular Carcinoma in Patients at High Risk: A Nationwide Nested Case-Control Study. Journal of Hepa-tology, 68, 476-484.</mixed-citation></ref><ref id="hanspub.44990-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Chiu, H.F., Ho, S.C., Chen, C.C. and Yang, C.-Y. (2011) Statin Use and the Risk of Liver Cancer: A Population-Based Case-Control Study. American Journal of Gastroenterology, 106, 894-898. &lt;br&gt;https://doi.org/10.1016/j.jhep.2017.10.018</mixed-citation></ref><ref id="hanspub.44990-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Shao, J.Y., Lee, F.P., Chang, C.L. and Wu, S.-Y. (2015) Statin-Based Palliative Therapy for Hepatocellular Carcinoma. Medicine, 94, e1801. &lt;br&gt;https://doi.org/10.1097/MD.0000000000001801</mixed-citation></ref><ref id="hanspub.44990-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">蒋美纯, 朱萱. 他汀类药物治疗慢性肝病有效性及安全性研究进展[J]. 中国实用内科杂志, 2020, 40(5): 423-427.</mixed-citation></ref></ref-list></back></article>